Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




A New Rapid Chlamydia Test Suitable for Clinical Labs and POC Use

By LabMedica International staff writers
Posted on 25 Dec 2013
Print article
Image: Microgram (500x) of human pap smear showing C. trachomatis in the vacuoles (Photo courtesy of Wikimedia Commons).
Image: Microgram (500x) of human pap smear showing C. trachomatis in the vacuoles (Photo courtesy of Wikimedia Commons).
A new rapid assay for Chlamydia trachomatis based on a state-of-the-art nucleic acid amplification technique detects as few as 5 to 12 pathogens per test within 20 minutes directly from urine samples without DNA purification.

Chlamydia trachomatis is the most common sexually transmitted human pathogen. Infections caused by this organism are a major public health concern because of the potential severe long-term consequences, including an increased risk of ectopic pregnancy, chronic pelvic pain, and infertility. However, approximately two-thirds of women with the infection experience minimal or no symptoms and therefore often go undiagnosed.

To date, several point-of-care tests have been developed for detection of C. trachomatis. Although many of them are fast and specific, they demonstrate only 10% to 40% sensitivity, which is inadequate for large-scale applications.

Investigators at Stockholm University (Sweden) and their colleagues at the University of Tartu (Estonia) have developed an improved test for the detection of C. trachomatis using recombinase polymerase amplification (RPA), a nucleic acid amplification technique that is based on the in vitro synthesis of many copies of DNA or RNA from one original template. The new assay amplifies nucleotide fragments of the C. trachomatis CDS2 gene from urine samples. The assay does not require purification of total DNA from the urine sample. Heating for five minutes at 90 °C is sufficient to release enough of the amplification target to determine whether the pathogen is present. While urine contains polymerase chain reaction (PCR) inhibitors, up to five microliters can be tested without affecting sensitivity of the RPA.

The investigators used the RPA assay to analyze urine samples from 70 patients (51 females and 19 males) attending a sexual health clinic in Estonia. The samples were tested in parallel with RPA and with the Roche (Basel, Switzerland) Cobas Amplicor C. trachomatis assay. Results revealed that 58 samples were negative in both assays (100% specificity). Twelve of the samples tested positive using the Roche assay. Of these, 10 tested positive and two tested negative in the RPA reaction. Based on these results, the clinical sensitivity of the RPA assay can be estimated at 83%.

"The alarmingly poor performance of the available POC tests for C. trachomatis has limited their wider use, and there is a clear requirement for more sensitive and cost-effective diagnostic platforms. Hence, the need for an applicable on-site test that offers reasonably sensitive detection," said senior author Dr. Ülo Langel, professor of molecular biotechnology at the University of Tartu and professor of neurochemistry at Stockholm University. "The [RPA] assay enables highly specific C. trachomatis detection with sensitivity levels significantly improved compared to currently available C. trachomatis POC assays."

The study was published in the January 2014 issue of the Journal of Molecular Diagnostics.

Related Links:

Stockholm University
University of Tartu
Roche


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.